Navigation Links
St. Mary Completes Phase 2 of Its Emergency Department and Trauma Center Expansion
Date:4/9/2013

d further evaluation are treated, has expanded from five to eight beds.

The Split-Flow Model is a new way to manage high patient volume.  When a patient enters the Emergency Department, s/he is immediately evaluated and directed to Pediatric, Prompt Care, Acute Care, or an Expedited Treatment Area.  This new implementation separates patients by the acuteness of their conditions and allows for them to be treated by healthcare providers as quickly as possible, helping to eliminate long wait times. These changes and improvements are intended to create an even more satisfying experience for patients.  According to benchmark data, St. Mary Emergency Department patient satisfaction is currently ranked in the top 5 percent nationally. "This recent expansion has had a very positive effect on both patients and physicians," notes Dr. Gary Zimmer , Medical Director of Emergency Services.  "Access to patient care has been improved, allowing us to effectively and efficiently treat the growing number of emergency patients.  The Split-Flow model of emergency care has had a tremendous impact on the quality of care patients receive."

In Phase 1 construction, each of the new private rooms added a television, bathroom facilities, computer for quick access to the patient's medical records, and a supply cart equipped with necessities for medical emergencies.  A new CAT scanner was installed within the Emergency Department in addition to the digital X-ray and full access to a range of diagnostic services used for patients.

The Bristol-Myers Squibb Pediatric Emergency Care Center benefited through the Phase 1 redesign.  In addition to being one of the first pediatric emergency care centers in the area, it is the only one in the region to implement the use of nitrous oxide (N2O) in treating children.  The practice of providing light sedation of N2O is a safe and effective way
'/>"/>

SOURCE St. Mary Medical Center
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
2. InnoPharma Completes $15 Million Series A Financing
3. Aratana Therapeutics Completes $15 Million Series B Financing
4. CeNeRx BioPharma Completes $4.85 Million Financing
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. MiMedx Group Completes $5,000,000 Private Placement
7. goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
8. Auxogyn Completes $20 Million In Series A Funding
9. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
10. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
11. Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , June 29, 2015 ... has announced the addition of the "Biotechnology ... Biotechnology for the Non-Biotechnologist, ideal for ... theory, principles, techniques and potential of biotechnology. ... understand the basic theory, principles, techniques, and potential ...
(Date:7/3/2015)... Texas (PRWEB) , ... July ... ... biotechnology company providing industry-leading products for use in applications such as animal ... in wastewater treatment plants and restaurant kitchen settings, announced today that it ...
(Date:7/3/2015)... 3, 2015 Forskere ... Innovation in Science", som finner sted i ... på nett, på  http://www.openinnovationinscience.at , og søknadsperioden ... De to største utfordringene innen helsevitenskapen ... nye forskningsspørsmål og kompleksiteten av nåværende forskningsresultater, ...
(Date:7/2/2015)... 2, 2015  Spherix Incorporated (Nasdaq: SPEX ) -- an ... monetization of intellectual property, today announced a litigation update. ... v. Verizon Services Corp. et al. , Case No. ... Eastern District of Virginia , the ... interpreting certain key claims in favor of the Defendants ...
Breaking Biology Technology:DryLet to Highlight Benefits of Patented ManureMagic™ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3
... is the first complement inhibitor to be tested ... Potentia Pharmaceuticals, a,privately held biotechnology company developing ... announced today that the Company,will be presenting its ... drug,candidate, POT-4, during the Retina Subspecialty Day at ...
... Oral Contraceptive,for the Prevention of Pregnancy, ... (NYSE: BRL ) today announced that ... approved its subsidiary Duramed Pharmaceuticals, Inc.,s New ... mg/0.02 mg and ethinyl estradiol tablets 0.01 ...
... Initiates Rosetta Green, a Project Which Will Leverage Rosetta Genomics, Proprietary microRNA Technologies and Strong IP ... Range of Plant-Based Applications, The Company has Recently Secured ... Trenches as Certain Milestones are ... Reached, Rosetta has Already Identified microRNAs Correlated With Algal Oil Content ...
Cached Biology Technology:Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting 2Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting 3FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 2FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 3FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 4FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 5Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 2Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 3Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 4
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:6/25/2015)... 25, 2015 According to ... (Swipe & Area), Technology, Material (Optical Prism, Piezoelectric, ... Security & Others) & Geography - Global Forecast ... said market is expected to reach $14,500.07 Million ... Browse 76 market Tables and 109 ...
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... requires activation of a molecule on the surface of B ... uses in its insidious attack on the immune system, University ... Conference (AIDS 2006). , "The research supports a new role ... between cells, with important implications for future studies and drug ...
... Health today provided the clearest picture yet of the prevalence ... with an increased risk of breast cancer. The genes are ... In addition, the study identified key predictors for assessing which ... , Each year, approximately 200,000 women in the United States ...
... with a rare disease in which patients develop multiple, benign ... found throughout the body, according to a report in the ... results from the loss of a gene called CYLD, causing ... studies indicated a role for CYLD in inflammation, but the ...
Cached Biology News:HIV infection requires an accomplice: B cells with special protein direct HIV to T cells 2New findings offer more complete view of breast cancer gene mutations in US population 2New findings offer more complete view of breast cancer gene mutations in US population 3Gene first linked to rare disease may trigger skin cancer, other tumors 2Gene first linked to rare disease may trigger skin cancer, other tumors 3
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
... an expertise in the forefront of chemical ... synthesis and synthesis in solution. , Our ... and analytical HPLC at no extra cost, ... the highest quality standard. , Our team ...
... The new Thermo Electron RapidStak provides ... tasks. Utilizing a unique buffer nest technology ... loading, the RapidStak provides fast, reliable automation ... productivity and walk-away confidence. The RapidStak can ...
Recombinant Rhesus Monkey IFN Alpha Activity: 2.9 x 10 8 u/mg...
Biology Products: